Tyra Biosciences has recorded sharply increasing net losses over recent years, culminating in a net loss of $119.9 million in 2025, reflecting an intensification of operating expenses largely linked to clinical development expansion. Despite these financial pressures, the company retains a strong liquidity position with a current ratio around 14.7 and cash reserves exceeding $77 million, cushioning operational flexibility. Recent management changes, including the appointment of an oncology-experienced COO, signal an emphasis on optimizing execution and commercial readiness. Analyst coverage beginning in early 2026 with overweight ratings indicates growing investor interest keyed to pipeline developments, especially the progressing Phase 2 clinical trial for dabogratinib in pediatric achondroplasia.